Drugs / P2202
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01674348 Comparator | Apr 2011 → Dec 2012 | type 2 diabetes mellitus | Piramal Enterprises Limited | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P2202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01674348 ↗ |
| Action | Inhibit | “Novel oral drug with potent and selective 11 beta-hydroxysteroid dehydrogenase type 1 (11b-HSD1) inhibitory properties” NCT01674348 ↗ |
| Route | Oral | “Novel oral drug” NCT01674348 ↗ |